Skip to Content
Merck
  • Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles.

Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles.

Journal of medicinal chemistry (2006-12-22)
Hirofumi Sasaki, Yoshikazu Haraguchi, Motohiro Itotani, Hideaki Kuroda, Hiroyuki Hashizume, Tatsuo Tomishige, Masanori Kawasaki, Makoto Matsumoto, Makoto Komatsu, Hidetsugu Tsubouchi
ABSTRACT

In an effort to develop potent new antituberculosis agents that would be effective against both drug-susceptible and drug-resistant strains of Mycobacterium tuberculosis, we prepared a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles substituted at the 2-position with various phenoxymethyl groups and a methyl group and investigated the in vitro and in vivo activity of these compounds. Several of these derivatives showed potent in vitro and in vivo activity, and compound 19 (OPC-67683) in particular displayed excellent in vitro activity against both drug-susceptible and drug-resistant strains of M. tuberculosis H37Rv (MIC = 0.006 microg/mL) and dose-dependent and significant in vivo efficacy at lower oral doses than rifampicin in mouse models infected with M. tuberculosis Kurono. The synthesis and structure-activity relationships of these new compounds are presented.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Rifampicin, suitable for plant cell culture, BioReagent, ≥95% (HPLC), powder or crystals
Pricing and availability is not currently available. Contact Technical Service
Sigma-Aldrich
Rifampicin, ≥95% (HPLC), powder or crystals
Pricing and availability is not currently available. Contact Technical Service
Sigma-Aldrich
Delamanid, ≥98% (HPLC)
Pricing and availability is not currently available. Contact Technical Service